Trial · NCT07905898
Evaluating and Promoting Resilience in Adolescents With Tourette Syndrome
NCT07905898, Not applicable, Not yet recruiting, Wake Forest University Health Sciences
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluating and Promoting Resilience in Adolescents With Tourette Syndrome. Trials, record NCT07905898. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07905898
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluating and Promoting Resilience in Adolescents With Tourette Syndrome
- NCT number
- NCT07905898
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 95 participants, estimated
- Lead sponsor
- Wake Forest University Health Sciences
- Conditions
- Tourette Syndrome, Tic Disorders, Persistent (Chronic) Motor or Vocal Tic Disorder
- Interventions
- PRISM Intervention, Usual care intervention
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Feasibility: Proportion of Participants Completing All Six Core PRISM Sessions (Aim 2) | Post-intervention (weeks 13-16, about 3-4 months) | Feasibility of the adapted PRISM intervention in the Aim 2 open trial, measured as the proportion of participants who complete all six core PRISM sessions (introductory session, four skills sessions, and family session), as recorded on the session attendance log. Feasibility is defined a priori as at least 80% of participants (12 or more of 15) completing all six sessions. |
| Primary | Feasibility of Intervention Measure (FIM) Mean Score (Aim 3 PRISM Arm) | Post-intervention (weeks 13-16, about 3-4 months) | Adolescent-rated feasibility of PRISM, measured with the 4-item Feasibility of Intervention Measure (FIM). Each item is rated from 1 (completely disagree) to 5 (completely agree), and the score is the mean of the 4 items (range 1-5). Higher scores indicate greater perceived feasibility. Feasibility is defined a priori as a mean score of 4 or higher. Measured in the Aim 3 PRISM + usual care arm only. |
| Secondary | Feasibility of Intervention Measure (FIM) Mean Score (Aim 2) | Post-intervention (weeks 13-16, about 3-4 months) | Adolescent-rated feasibility of PRISM in the Aim 2 open trial, measured with the 4-item Feasibility of Intervention Measure (FIM). Each item is rated from 1 (completely disagree) to 5 (completely agree), and the score is the mean of the 4 items (range 1-5). Higher scores indicate greater perceived feasibility. |
| Secondary | Acceptability of Intervention Measure (AIM) Score | Post-intervention (weeks 13-16, about 3-4 months) | Adolescent-rated acceptability of PRISM, measured with the 4-item Acceptability of Intervention Measure (AIM). Each item is rated from 1 (completely disagree) to 5 (completely agree), and the score is the mean of the 4 items (range 1-5). Higher scores indicate greater acceptability. Measured in participants who receive PRISM (Aim 2 and the Aim 3 PRISM + usual care arm). |
| Secondary | Intervention Appropriateness Measure (IAM) Mean Score | Post-intervention (weeks 13-16, about 3-4 months) | Adolescent-rated appropriateness (perceived fit and relevance) of PRISM, measured with the 4-item Intervention Appropriateness Measure (IAM). Each item is rated from 1 (completely disagree) to 5 (completely agree), and the score is the mean of the 4 items (range 1-5). Higher scores indicate greater appropriateness. Measured in participants who receive PRISM (Aim 2 and the Aim 3 PRISM + usual care arm). |
| Secondary | Recruitment: Proportion of Eligible Participants Who Consent | At the end of enrollment for each Aim | Number of participants who provide informed consent (and assent, if applicable) divided by the number who screen eligible, as recorded on the screening log and enrollment tracker. Reported separately for each Aim. |
| Secondary | Data Completeness: Proportion of Participants Completing All Study Questionnaires | Baseline, post-intervention (weeks 13-16, about 3-4 months), and week 26 (about 6 months; Aim 3 only) | Proportion of enrolled participants who complete all scheduled self-report questionnaires and clinician-rated assessments at each assessment timepoint. |
| Secondary | Intervention Fidelity: Percentage of PRISM Session Components Delivered | Throughout the intervention period (weeks 1-16, about 4 months) | Audio-recorded PRISM sessions are scored by the PRISM team using PRISM's standardized session fidelity checklists, which rate each required session component as covered or not covered. The first 3 sessions and then 1 in 3 randomly selected sessions per interventionist are reviewed. Reported as the mean percentage of checklist components covered across reviewed sessions. |
| Secondary | Resilience: Connor-Davidson Resilience Scale-10 (CD-RISC-10) Total Score | Baseline, post-intervention (weeks 13-16, about 3-4 months), and week 26 (about 6 months; Aim 3 only) | 10-item adolescent self-report measure of resilience over the past month. Items are rated from 0 (not true at all) to 4 (true nearly all the time) and summed for a total score of 0-40. Higher scores indicate greater resilience. In Aim 3, the between-group difference (PRISM + usual care vs. usual care alone) in change from baseline will be estimated. |
| Secondary | Tic Severity: Yale Global Tic Severity Scale (YGTSS) Total Tic Severity Score | Baseline, post-intervention (weeks 13-16, about 3-4 months), and week 26 (about 6 months; Aim 3 only) | Clinician-rated, semi-structured interview of tic symptoms over the past week, completed with the adolescent and, for ages 12-17, a parent/caregiver. Motor and phonic tics are each rated on number, frequency, intensity, complexity, and interference (0-5 each), giving a Total Motor score (0-25) and Total Phonic score (0-25), which are summed for a Total Tic Severity score (0-50). Higher scores indicate more severe tics. For participants with persistent motor or vocal tic disorder, the score is capped at 25, and Total Motor and Total Phonic scores are also reported separately. In Aim 3, post-randomization ratings are completed by a blinded assessor. |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| K23MH141319 | Evaluating and Promoting Resilience in Adolescents with Tourette Syndrome | Martindale, Jaclyn | WAKE FOREST UNIVERSITY HEALTH SCIENCES | NATIONAL INSTITUTE OF MENTAL HEALTH | 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07905898
GET https://conductscience.org/api/trials/v1/NCT07905898/registered?page=2